Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezigdomide PK in Renal Impairment
NCT06318676Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2024
- Primary completion
- Nov 2024
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of mezigdomide in multiple myeloma (MM) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum observed concentration up to 24 days, Area under the plasma concentration-time curve up to 24 days and 1 more. Started Mar 2024; status: completed.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06318676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06318676.